BofA/Merrill raised its price target for GW Pharmaceuticals to $155 after the company last night presented updated data from its investigator-sponsored trials for epidiolex. The firm raised its probability of approval for Dravet's to 40% from 35% and for Lennox-Gastaut syndrome to 20% from 15%. The analysts pointed to a "high level of excitement" from the doctors it spoke to regarding epidiolex's cognitive benefits on top of efficacy when compared to current therapies. BofA/Merrill keeps a Buy rating on GW Pharmaceuticals. The stock is up $2.52 to $115.56 in midday trading.